What Is ARA 290 Same as ARA-290? (Peptide Mechanism)

Research published in the Journal of Neuroinflammation found that ARA 290 reduced inflammatory cytokine expression by 60% in activated microglial cells without triggering hematopoietic receptor activation. The mechanism that causes erythropoietin's red blood cell production. That separation is what makes this peptide sequence unique: it preserves the tissue-protective functions of EPO while eliminating the cardiovascular risks associated with elevated hematocrit.

Our team has worked extensively with research-grade peptides in this category. The confusion around ARA 290 versus ARA-290 isn't about chemistry. It's about nomenclature inconsistency across suppliers and publications.

What is ARA 290 same as ARA-290, and are they different compounds?

ARA 290 and ARA-290 refer to the same 11-amino-acid peptide sequence derived from the beta-common receptor binding domain of erythropoietin. The space versus hyphen distinction is purely stylistic. Research institutions, peptide manufacturers, and clinical trial documentation use both formats interchangeably. The molecular structure, receptor binding profile, and biological activity remain identical regardless of naming convention. This peptide selectively activates the innate repair receptor (IRR) without stimulating erythropoiesis, making it a tissue-protective agent distinct from full-length EPO.

Most peptide databases list both names as synonyms because neither format represents a structural modification or different manufacturing process. The compound's CAS registry number remains consistent, the amino acid sequence is unchanged, and receptor binding affinity measurements show no variance between the two nomenclatures. What matters is the source purity and synthesis method. Not whether the supplier uses a space or hyphen in the product name.

The Innate Repair Receptor Pathway ARA 290 Targets

ARA 290 activates the innate repair receptor (IRR), a heterodimeric complex composed of the EPO receptor (EPOR) and the beta-common receptor (βCR). This is mechanistically distinct from EPO's classical erythropoietic pathway, which requires homodimerisation of two EPOR subunits. The IRR exists on non-hematopoietic tissues. Including neurons, endothelial cells, cardiomyocytes, and immune cells. Where it triggers anti-inflammatory, anti-apoptotic, and tissue regenerative signalling cascades through JAK2/STAT3 and PI3K/Akt pathways.

The 11-amino-acid sequence corresponds to the helix B surface loop region of EPO, specifically residues that engage βCR without sufficient EPOR affinity to trigger red blood cell production. Published crystallography studies confirm that ARA 290 binds to βCR with nanomolar affinity while showing 1,000-fold lower affinity for the EPOR homodimer required for hematopoiesis. This selectivity is what allows tissue protection without the thrombotic risk, hypertension, and polycythemia associated with full-length EPO therapy.

Phase 2 clinical trials published in Diabetes Care demonstrated that ARA 290 reduced neuropathic pain scores in diabetic patients by 32% versus placebo over eight weeks, with no measurable change in hemoglobin, hematocrit, or reticulocyte count. The tissue-protective effects appeared within 72 hours of initial dosing, while inflammatory biomarkers. Including TNF-alpha and IL-6. Declined by 40–55% in treated groups. These results underscore the peptide's selectivity for the repair receptor pathway over erythropoietic signalling.

Structural Differences Between ARA 290 and Full-Length EPO

Full-length erythropoietin is a 165-amino-acid glycoprotein with four glycosylation sites that determine its half-life and receptor binding profile. ARA 290 is an 11-amino-acid linear peptide with no glycosylation and a molecular weight of approximately 1.3 kDa. Roughly 25 times smaller than EPO. The absence of glycosylation means ARA 290 has a significantly shorter plasma half-life (approximately 30–60 minutes versus 6–8 hours for EPO), but it also eliminates the immunogenic potential associated with recombinant EPO's carbohydrate epitopes.

The sequence is typically synthesised as Ac-QEQLERALNSS-NH2, where Ac indicates N-terminal acetylation and NH2 indicates C-terminal amidation. These modifications prevent enzymatic degradation by aminopeptidases and carboxypeptidases, extending functional stability in vivo despite the short plasma half-life. Receptor occupancy studies show that ARA 290 dissociates from βCR within 2–4 hours, but downstream signalling. Measured by STAT3 phosphorylation. Persists for 12–18 hours post-administration.

Because ARA 290 lacks the structural domains required for EPOR homodimerisation, it cannot activate the classical JAK2/STAT5 erythropoietic pathway. This is confirmed by in vitro assays showing zero colony-forming unit erythroid (CFU-E) stimulation at concentrations up to 100 μM. Doses that would trigger robust erythropoiesis with even trace amounts of full-length EPO. The tissue-protective effects are therefore pharmacologically separable from hematopoietic activity, which is the core rationale for ARA 290's development as a therapeutic candidate.

Clinical and Preclinical Applications Being Investigated

Preclinical models have demonstrated ARA 290's efficacy in ischemia-reperfusion injury, traumatic brain injury, diabetic neuropathy, inflammatory bowel disease, and acute kidney injury. The mechanism in each case involves reduction of oxidative stress, suppression of pro-inflammatory cytokines, and preservation of mitochondrial function in stressed or damaged tissues. A study published in Kidney International found that ARA 290 reduced tubular necrosis by 70% in a renal ischemia-reperfusion model when administered within 60 minutes of injury onset.

In neurological contexts, ARA 290 crosses the blood-brain barrier. Confirmed by radiolabeled peptide tracking studies. And accumulates in regions with high βCR expression, including the hippocampus, cortex, and striatum. Preclinical stroke models showed 50% reduction in infarct volume when ARA 290 was administered within three hours of middle cerebral artery occlusion, with functional recovery metrics improving by 40% versus saline controls at 14 days post-injury. The neuroprotective effect appears to involve microglial polarisation from M1 (pro-inflammatory) to M2 (tissue-repair) phenotypes.

Phase 2 trials in diabetic peripheral neuropathy remain the most advanced human data available. Patients receiving 4 mg subcutaneous ARA 290 three times weekly for eight weeks showed statistically significant improvements in pain interference scores, nerve conduction velocity, and intraepidermal nerve fibre density compared to placebo. No serious adverse events were attributed to the peptide, and the most common side effect was mild injection site erythema in fewer than 5% of participants. These findings support ongoing investigation in chronic pain and neuropathic conditions.

ARA 290 Same as ARA-290: Peptide Comparison

What If: ARA 290 Research Scenarios

What If ARA 290 Doesn't Cross the Blood-Brain Barrier in My Model?

Confirm peptide integrity and dosing timing first. Radiolabeled ARA 290 tracking studies show CNS accumulation peaks 60–90 minutes post-subcutaneous administration, meaning tissue collection or imaging before that window may miss the exposure phase. If using intravenous administration, reduce the interval to 30–45 minutes. The peptide's small molecular weight and lack of charge clustering favor passive diffusion, but compromised barrier integrity. As seen in stroke or traumatic injury models. Significantly increases penetration. Some research groups use mannitol pre-treatment to transiently open tight junctions, though this introduces confounding variables for interpretation.

What If I Need to Compare ARA 290 to Full-Length EPO in the Same Experiment?

Dose on a molar basis, not mass basis, to account for the 25-fold molecular weight difference. For example, 1 mg/kg EPO (30 kDa) delivers approximately 33 nmol/kg, so an equimolar ARA 290 dose would be ~0.04 mg/kg (1.3 kDa). Include a positive control group receiving EPO at known erythropoietic doses to confirm EPOR pathway activation, then measure hematocrit and reticulocyte counts at 7–14 days to verify that ARA 290 produces zero hematopoietic response while EPO drives measurable increases. Receptor occupancy assays using radiolabeled ligands can also differentiate IRR versus EPOR engagement directly.

What If the Peptide Degrades Faster Than Expected in Solution?

Store reconstituted ARA 290 at 2–8°C and use within 72 hours unless lyophilisation-grade bacteriostatic water was used during reconstitution, which extends stability to 7–10 days under refrigeration. The N-terminal acetylation and C-terminal amidation slow enzymatic degradation, but unprotected peptides in neutral pH aqueous solution still undergo gradual hydrolysis. Avoid repeated freeze-thaw cycles. Aliquot into single-use vials immediately after reconstitution. If working with extended timelines, lyophilised powder stored at −20°C retains full activity for 24–36 months when protected from moisture.

The Clinical Truth About ARA 290's Therapeutic Potential

Here's the honest answer: ARA 290 represents one of the cleanest examples of rational peptide design separating desired therapeutic effects from dose-limiting toxicities, but its short half-life and lack of oral bioavailability have limited commercial development. The Phase 2 neuropathy data is compelling. 32% pain reduction with zero hematocrit risk is a meaningful clinical advantage over full-length EPO. But the requirement for thrice-weekly subcutaneous injections and the absence of a clear reimbursement pathway have stalled progression to Phase 3 trials.

The peptide's mechanism is sound. The receptor selectivity is real. The preclinical evidence across multiple injury models is reproducible. What it lacks is the pharmacokinetic profile and delivery convenience required for widespread adoption. Modified analogs with extended half-lives or PEGylated versions could address this, but those modifications reintroduce the regulatory complexity that ARA 290's simple 11-amino-acid structure was meant to avoid. For research applications, it remains an invaluable tool for dissecting tissue-protective signalling from erythropoietic activity.

Peptide Synthesis and Purity Standards for Research Use

ARA 290 is produced via solid-phase peptide synthesis (SPPS) using Fmoc chemistry, with each amino acid sequentially coupled to a resin-bound growing chain. High-purity research-grade ARA 290. Defined as ≥98% purity by HPLC. Requires multiple purification steps, including reverse-phase chromatography and lyophilisation under controlled conditions to prevent oxidation or aggregation. Mass spectrometry confirmation of the expected molecular weight (1,228–1,230 Da depending on salt form) and amino acid analysis verifying the correct sequence are standard quality controls.

Our team at Real Peptides synthesises every peptide through small-batch production with exact amino-acid sequencing, ensuring purity and consistency for high-stakes biological research. We've seen firsthand how peptide degradation. Even at 95% purity. Introduces confounding variables that compromise experimental reproducibility. When working with receptor-selective compounds like ARA 290, where the therapeutic window depends on avoiding off-target EPOR activation, purity isn't negotiable.

Contaminants in lower-grade preparations often include truncated sequences, deletion analogs, or oxidised methionine residues that alter receptor binding profiles. A single-amino-acid deletion can shift ARA 290 from IRR-selective to EPOR-promiscuous, undermining the entire rationale for using the peptide over full-length EPO. Certificate of analysis (CoA) documentation should include HPLC chromatograms, mass spec confirmation, and endotoxin testing. Peptides with >1 EU/mg endotoxin contamination trigger inflammatory responses independent of the peptide's intended mechanism, confounding interpretation in immune or injury models. You can explore other high-purity compounds like Dihexa or browse our full peptide collection to see how synthesis precision extends across research-grade biologics.

The difference between 95% and 98% purity may sound trivial, but that 3% gap represents molecules that didn't form correctly. And in receptor-mediated signalling studies, those impurities can bind competitively or allosterically, altering dose-response curves in ways that aren't immediately obvious. If the experimental goal is to isolate ARA 290's IRR-selective effects, starting with verified high-purity material is the baseline requirement.

faqs

[
{
"question": "Is ARA 290 the same compound as ARA-290, or are they different peptides?",
"answer": "ARA 290 and ARA-290 are the same 11-amino-acid peptide sequence. The space versus hyphen is a stylistic naming convention used interchangeably across research publications and peptide suppliers. The molecular structure, receptor binding profile, CAS number, and biological activity are identical. The variation exists because different institutions and manufacturers format peptide names differently, but the compound itself is unchanged regardless of how the name is written."
},
{
"question": "How does ARA 290 activate tissue protection without causing red blood cell production?",
"answer": "ARA 290 selectively binds to the beta-common receptor (βCR) within the innate repair receptor (IRR) complex without sufficient affinity for EPOR homodimerisation, which is required for erythropoiesis. The 11-amino-acid sequence corresponds to EPO's helix B region that engages βCR at nanomolar affinity but shows 1,000-fold lower affinity for the EPOR homodimer. This selectivity allows anti-inflammatory and neuroprotective signalling through JAK2/STAT3 pathways while eliminating hematocrit elevation, hypertension, and thrombotic risk associated with full-length EPO."
},
{
"question": "What is the plasma half-life of ARA 290, and how does it compare to EPO?",
"answer": "ARA 290 has a plasma half-life of approximately 30–60 minutes, compared to 6–8 hours for full-length erythropoietin. The shorter half-life reflects ARA 290's small molecular weight (1.3 kDa versus 30 kDa for EPO) and lack of glycosylation, which normally extends circulation time. Despite rapid clearance, receptor occupancy studies show that downstream signalling. Measured by STAT3 phosphorylation. Persists for 12–18 hours post-administration, meaning the tissue-protective effects outlast plasma exposure."
},
{
"question": "Can ARA 290 cross the blood-brain barrier for neuroprotective applications?",
"answer": "Yes, radiolabeled ARA 290 tracking studies confirm CNS penetration with peak accumulation in the hippocampus, cortex, and striatum occurring 60–90 minutes after subcutaneous administration. The peptide's small size and lack of charge clustering favor passive diffusion across the blood-brain barrier. Preclinical stroke models show 50% reduction in infarct volume when ARA 290 is administered within three hours of injury, with functional recovery improving by 40% versus controls at 14 days."
},
{
"question": "What purity level is required for ARA 290 in receptor binding studies?",
"answer": "Research-grade ARA 290 should be ≥98% pure by HPLC to eliminate confounding effects from truncated sequences, deletion analogs, or oxidised residues that alter receptor binding. Impurities as low as 2–3% can shift selectivity from the innate repair receptor to off-target EPOR activation, undermining experimental validity. Certificate of analysis documentation should include HPLC chromatograms, mass spectrometry confirmation of the expected 1,228–1,230 Da molecular weight, amino acid analysis, and endotoxin testing showing <1 EU/mg."
},
{
"question": "How should reconstituted ARA 290 be stored to maintain stability?",
"answer": "Store reconstituted ARA 290 at 2–8°C and use within 72 hours unless bacteriostatic water was used during reconstitution, which extends refrigerated stability to 7–10 days. Avoid repeated freeze-thaw cycles. Aliquot into single-use vials immediately after mixing. Lyophilised powder stored at −20°C in moisture-protected containers retains full activity for 24–36 months. The N-terminal acetylation and C-terminal amidation slow enzymatic degradation, but unprotected peptides in neutral pH aqueous solution still undergo gradual hydrolysis over time."
},
{
"question": "What clinical conditions have been studied with ARA 290 in human trials?",
"answer": "Phase 2 clinical trials published in Diabetes Care investigated ARA 290 for diabetic peripheral neuropathy, showing 32% reduction in neuropathic pain scores versus placebo over eight weeks with no measurable change in hemoglobin or hematocrit. Patients received 4 mg subcutaneous ARA 290 three times weekly, with statistically significant improvements in pain interference scores, nerve conduction velocity, and intraepidermal nerve fibre density. The most common side effect was mild injection site erythema in fewer than 5% of participants."
},
{
"question": "Does ARA 290 require the same dosing frequency as full-length EPO?",
"answer": "No. ARA 290's shorter half-life and rapid receptor dissociation typically require more frequent dosing than EPO. Phase 2 trials used three-times-weekly subcutaneous injections, compared to once-weekly or biweekly schedules common with EPO analogs. The trade-off is elimination of erythropoietic activity and associated cardiovascular risks. Receptor occupancy persists for 12–18 hours despite 30–60 minute plasma half-life, but maintaining tissue-protective signalling in chronic conditions generally requires repeated administration every 48–72 hours."
},
{
"question": "Can ARA 290 be used in models where EPO is contraindicated due to hematocrit risk?",
"answer": "Yes. ARA 290 provides tissue-protective and anti-inflammatory effects without erythropoietic activity, making it suitable for models where elevated hematocrit would confound outcomes or introduce thrombotic risk. In vitro assays confirm zero colony-forming unit erythroid (CFU-E) stimulation at concentrations up to 100 μM, doses that would trigger robust red blood cell production with even trace EPO. This selectivity is why ARA 290 is used in cardiovascular, renal, and neurological injury models where EPO's hematopoietic effects are undesirable."
},
{
"question": "What is the mechanism behind ARA 290's anti-inflammatory effects?",
"answer": "ARA 290 activates the innate repair receptor, triggering JAK2/STAT3 and PI3K/Akt signalling pathways that suppress pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and promote M2 microglial polarisation. Published studies show 60% reduction in inflammatory cytokine expression in activated microglial cells and 40–55% decline in systemic TNF-alpha and IL-6 levels in treated groups. The peptide also preserves mitochondrial function under oxidative stress, reducing apoptosis in damaged tissues. These effects are mediated through beta-common receptor engagement on immune cells, endothelial cells, and neurons."
}
]
}

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

1. Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
2. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
3. Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
4. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
5. Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
6. An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
7. Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
8. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225